Analyst Price Targets — MDXG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 6:49 am | — | UBS | $10.00 | $5.17 | StreetInsider | Citizens Starts MiMedx Group (MDXG) at Market Outperform |
| November 15, 2024 11:48 am | Anthony Petrone | Mizuho Securities | $16.00 | $9.09 | StreetInsider | MiMedx Group (MDXG) PT Raised to $16 at Mizuho |
| July 2, 2024 6:15 am | Ross Osborn | Cantor Fitzgerald | $11.00 | $6.70 | TheFly | MiMedx initiated with an Overweight at Cantor Fitzgerald |
| April 29, 2024 8:43 am | Brooks O'Neil | Lake Street | $12.00 | $6.27 | TheFly | Proposed new LCDs likely benefit MiMedx if implemented, says Lake Street |
| September 7, 2022 6:20 am | — | H.C. Wainwright | $8.00 | $3.42 | Benzinga | HC Wainwright & Co. Maintains Buy on MiMedx Group, Lowers Price Target to $8 |
Latest News for MDXG
MARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced a series of cost reduction initiatives intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses.
JPMorgan Chase and Co. reduced its holdings in shares of MiMedx Group, Inc (NASDAQ: MDXG) by 21.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 493,661 shares of the company's stock after selling 133,744 shares during the period. JPMorgan Chase and Co. owned about 0.33%
Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its participation in two leading wound care conferences: the Symposium on Advanced Wound Care (“SAWC”) Spring 2026 and MedStar…
MiMedx Group (NASDAQ: MDXG - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Volatility and Risk MiMedx Group has a beta
Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MDXG.
U.S. House Trading
No House trades found for MDXG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.